tbuckley/cabot-search huggingface dataset:
P-287 Retrospective real-world data study using natural language processing to describe treatment sequence and clinicopathological patterns in patients with metastatic colorectal cancer in five Spanish institutions
Authors: R. Vera García, L. Abella, J. Aparicio Urtasun, D. Gutierrez Abad, A. López Alfonso, R. Mondéjar Solís
Journal: Annals of Oncology (2023)
SO-6 Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group
Authors: L. Weiss, V. Heinemann, L. Fischer, F. Gieseler, T. Hoehler, J. Mayerle, D. Quietzsch, A. Reinacher-Schick, M. Schenk, G. Seipelt, J. Siveke, M. Stahl, U. Vehling-Kaiser, D. Waldschmidt, K. Dorman, D. Zhang, B. Westphalen, M. Haas, S. Boeck
Journal: Annals of Oncology (2023)
P-68 Impact of specimens and fixation status on HER2 assessment in the treatment of advanced gastric cancer (HER_WEEKEND study)
Authors: M. Nakamura, A. Watanabe, A. Yoshizawa, S. Iwasaki, A. Nomura, M. Matsumura, T. Murai, K. Itaya, Y. Koike, T. Izumi, A. Endo, S. Kato, Y. Ono, T. Ohshima, N. Okazaki, S. Nakagawa, Y. Ishii, I. Yokota, T. Tsuji, S. Nishikawa
Journal: Annals of Oncology (2023)
P-95 Long-term effectiveness results and prognostic predictors for overall survival from CIREL – the real-world multi-centre, observational cohort on irinotecan-eluting transarterial chemoembolization in CRLM
Authors: H. Prenen, D. Arnold, B. Sangro, B. Zeka, N. Kaufmann, A. Gjoreski, R. Iezzi, P. Pereira, J. Taieb
Journal: Annals of Oncology (2023)
P-236 Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS mutant metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
Authors: J. Lucchetti, L. Angotti, A. Cortellini, M. Basso, M. Polito, F. Zoratto, E. Di Giacomo, M. Calegari, F. Lo Prinzi, D. Gemma, C. Signorelli, M. Veroli, A. Anghelone, L. Galbato Muscio, B. Di Cocco, G. Trombetta, S. Guerriero, F. Schietroma, B. Vincenzi, G. Tonini
Journal: Annals of Oncology (2023)
P-274 Real-world evidence for dose reduced preoperative chemotherapy in the older population with resectable gastroesophageal cancer
Authors: J. Skjoldbirk, K. Egebjerg, C. Qvortrup, C. Lund, L. Baeksgaard, M. Achiam, P. Mau-Soerensen
Journal: Annals of Oncology (2023)
P-381 Management of EaRly-onset MetastatIc cOlorectal caNcEr (ERMIONE): A single institution analysis
Authors: G. Valente, A. Di Bello, A. Anghelone, F. Schietroma, V. Beccia, G. Caira, A. Spring, G. Trovato, A. Ceccarelli, L. Chiofalo, S. Perazzo, M. Bensi, M. Basso, C. Pozzo, L. Salvatore, M. Calegari, G. Tortora
Journal: Annals of Oncology (2023)
P-209 Real-world study of durvalumab and chemotherapy in Indian patients with advanced biliary tract cancers
Authors: V. Muddu, A. Shah, A. Raj, A. Bahl, R. Thirumalairaj, J. Ghosh, V. Ostwal, S. Rajappa, A. Vora, V. Lavingia, A. Sharma, A. Khan, N. Rohatgi, M. Mahajan, M. Chandrakanth, A. Ramaswamy
Journal: Annals of Oncology (2023)
P-413 NER repair system and predisposition to hereditary colorectal cancer: ERCC1 novel mutation in a Tunisian family
Authors: A. Jaballah-Gabteni, S. Ben Nasr, I. Ben Ayed, H. Yaïche, N. Ben Jemii, D. Wider, T. Laasili, A. Haddauoi, S. Boubaker, H. Guettiti Tounsi-Kettiti
Journal: Annals of Oncology (2023)
PD-17 Multicentric prospective study assessing clinical benefit of targeted treatment for patients with biliary tract cancers
Authors: M. Niger, F. Nichetti, C. Soldà, T. Pressiani, C. Bagalà, G. Masi, C. Pircher, M. De Grandis, G. Barsotti, V. Zanuso, M. Bensi, V. Genovesi, G. Pruneri, G. Ricagno, L. Rimassa, L. Salvatore, C. Vivaldi, F. Bergamo, F. Pietrantonio, F. de Braud, S. Lonardi
Journal: Annals of Oncology (2023)
P-102 Unmet needs of patients during colorectal cancer care and treatment – a qualitative study through an online patient community
Authors: E. Samalin, L. Lorenzon, C. Sarrauste de Menthière, L. Guéroult-Accolas, R. Paixão, C. Chaves Almagro, E. Pain, E. Martinelli
Journal: Annals of Oncology (2023)
LBA-1 The Phase III Study: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for locally advanced pancreatic cancer (TIGeR-PaC)
Authors: M. Pishvaian, C. Lopez, E. Zervos, H. Hatoum, D. Berg, A. Ucar, B. Boone, T. Johnson, A. Zureikat, M. Kenneth, K. Chung, R. Gandhi, R. Nazemzadeh, N. Parikh, P. Novelli, B. Kouri, C. Laing, S. Bates, R. Agah, K. Goodman
Journal: Annals of Oncology (2023)
P-160 Mismatch repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy
Authors: A. Pretta, P. Ziranu, R. Giampieri, G. Pinna, G. Randon, C. Donisi, A. Ravarino, F. Loi, G. Deias, E. Palmas, F. Morano, C. Solinas, E. Lai, M. Puzzoni, V. Pusceddu, A. Restivo, L. Zorcolo, R. Berardi, G. Faa, F. Pietrantonio, M. Scartozzi
Journal: Annals of Oncology (2023)
P-41 Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data
Authors: M. Rimini, L. Fornaro, S. Lonardi, M. Niger, J. Lucchetti, G. Giordano, M. Scartozzi, E. Tamburini, I. Rapposelli, E. Martinelli, I. Garajová, M. Schirripa, L. Rimassa, L. Antonuzzo, A. Casadei Gardini
Journal: Annals of Oncology (2023)
P-91 Landscape of BRAF-V600E mutant colorectal cancer management in Latin America
Authors: A. Coutinho, M. Cavalcante Gifoni, A. Jansen, M. Rico-Restrepo, J. O’Connor, G. Sanku, G. Mendez, J. Samamé Pérez-Vargas, C. Blanco
Journal: Annals of Oncology (2023)
P-237 Esophageal microbiome correlates with post-esophagectomy anastomotic leak in cancer patients
Authors: R. Naddaf, H. Shmilovich, S. Carasso, H. Kashtan, S. Markaer, M. Nilsson, T. Goshen-Lago, T. Geffen, N. Geva-Zatorsky, I. Ben-Aharon
Journal: Annals of Oncology (2023)
P-119 HGCSG 1803: Single-arm phase Ⅱ study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment
Authors: K. Sawada, S. Nakano, Y. Kawamoto, T. Miyagishima, S. Sogabe, Y. Kobayashi, K. Ito, A. Sato, Y. Chen, M. Dazai, K. Harada, S. Yuki, I. Yokota, Y. Komatsu
Journal: Annals of Oncology (2023)
PD-25 Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colorectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study
Authors: G. Prager, J. Kisro, H. Müller-Huesmann, E. von der Heyde, P. Stübs, D. Bürkle, B. Schmidt, H. Forstbauer, N. Hagemeyer, F. Reichenbach, D. Arnold, R. Fritsch, A. Gerger, S. Hegewisch-Becker, A. Vogel, A. Wagner, T. Winder, D. Koeberle, S. Stintzing
Journal: Annals of Oncology (2023)
P-159 Association of acrochordons and colorectal polyps: A pilot study to identify potential genetic or viral etiology
Authors: B. Gafton, E. Froicu, V. Afrasanie, I. Prutianu, T. Alexa Stratulat, A. Ivanov, I. Radu, D. Scripcariu
Journal: Annals of Oncology (2023)
SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)
Authors: M. Germani, R. Moretto, J. Ros, R. Intini, F. Ghelardi, G. Vetere, R. Toledo, F. Bergamo, G. Randon, E. Elez, S. Lonardi, S. Oldani, M. Giordano, D. Rossini, W. Ferrari Bravo, G. Ricagno, P. Vignali, C. Ugolini, G. Fontanini, C. Cremolini
Journal: Annals of Oncology (2023)
P-93 Safety and feasibility of irradiation and nivolumab in esophageal cancer – a phase I/II study
Authors: G. Hjortland, K. Aasand, T. Kumar, E. Hernes, B. Knutsen, Y. Nilssen, J. Kyte, T. Guren, T. Hauge, H. Johannessen
Journal: Annals of Oncology (2023)
P-175 Next-generation sequencing in colorectal cancer patients: Characterization and prognostic implications
Authors: F. Longo, J. Pozas, P. Reguera Puertas, M. Delfrade, A. Barrill Corpa, J. Calvo, R. Fuentes Mateos, C. Guillén-Ponce, M. Rodriguez Garrote, V. López Gómez, J. Serrano Domingo, M. Vaz, M. Villamayor Delgado, M. Lario, A. Santón, A. Ferrer, I. Ruz, A. Caminoa, L. Perna, J. Palacios, P. Garrido, R. Ferreiro Monteagudo
Journal: Annals of Oncology (2023)
P-116 Clinical utility of circulating tumor DNA (ctDNA) in patients with early/resected biliary tract cancer (BTC)
Authors: J. Yu, R. Mehta, D. Anaya, J. Denbo, C. Bridges, K. Manage, A. Tin, V. Aushev, S. Sharma, A. Jurdi, M. Liu, R. Kim
Journal: Annals of Oncology (2023)
P-118 Clinical significance of primary tumor sites and epithelial tumor markers in patients with unresectable/recurrent gastrointestinal neuroendocrine carcinoma treated with combined chemotherapy with irinotecan and cisplatin
Authors: K. Fukuda, H. Osumi, O. Akira, S. Udagawa, I. Nakayama, S. Fukuoka, T. Wakatsuki, M. Ogura, D. Takahari, K. Chin, K. Yamaguchi, E. Shinozaki
Journal: Annals of Oncology (2023)
SO-1 A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
Authors: J. Harding, M. Ikeda, L. Goyal, J. Rodon, L. Bai, D. Oh, J. Park, L. Chen, M. Ueno, C. Liao, S. Kondo, R. Cosman, T. Yokota, R. Shroff, T. Satoh, L. Palmieri, A. Hollebecque, J. Adeva, M. Bender, H. Liu, T. Macarulla
Journal: Annals of Oncology (2023)
P-221 Prediction of colon cancer recurrence based on proteomic biomarkers
Authors: S. Cameselle-Garcia, M. Salgado Fernandez, A. Fernández-Montes, N. Garcia Cid, R. Alvarez Llosa, M. Penin Corderi, F. Gude-Sampedro, J. García Gómez, J. Garcia Mata, I. Abdulkader Nallib, S. Bravo López
Journal: Annals of Oncology (2023)
P-231 Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)
Authors: B. Weinberg, A. He, B. Tan, A. Turk, M. Noel, J. Marshall, M. Sung, H. Wang, C. Ferguson, N. Swanson, K. Pedersen
Journal: Annals of Oncology (2023)
P-109 Broaden the therapeutic opportunities for colorectal cancer: ALK inhibition benefits consensus molecular subtype 1 patients
Authors: M. Mazzeschi, M. Sgarzi, D. Romaniello, F. Ambrosi, A. Morselli, C. Girone, F. Pagano, K. Rihawi, G. D'Uva, M. Ferracin, M. Fiorentino, A. Ardizzoni, B. Győrffy, R. Palmer, N. Li, C. Lengner, Y. Mossé, M. Lauriola
Journal: Annals of Oncology (2023)
P-172 VOLTAGE cohort D: Preoperative chemoradiotherapy followed by consolidation nivolumab plus ipilimumab in patients with locally advanced rectal cancer
Authors: Y. Takahashi, T. Kato, H. Bando, Y. Tsukada, K. Inamori, M. Wakabayashi, S. Kumagai, S. Koyama, D. Kotani, S. Yuki, Y. Komatsu, S. Homma, A. Taketomi, M. Uemura, M. Fukui, M. Kojima, A. Sato, H. Nishikawa, M. Ito, T. Yoshino
Journal: Annals of Oncology (2023)
P-390 Micronutrient insufficiency after surgery for oesophagogastric neoplasms: A prospective intervention study VITAMin Insufficiency in oesophagogastric Neoplasms or the VITAMIN study
Authors: A. van der Velden, T. Vermeer, E. Boerma, E. Belgers, J. Stoot, M. Leers, M. Sosef, G. Vijgen
Journal: Annals of Oncology (2023)
P-242 Characterisation of KRAS mutations in patients with metastatic colorectal cancer: A single institution experience
Authors: M. Alameda, A. Rueda-Lara, D. Viñal, P. Zwisler Contreras, G. Martin-Montalvo, I. Ruiz-Gutierrez, J. Peña, D. Jimenez-Bou, D. Martinez Perez, J. Pedregosa Barbas, J. Garcia-Cuesta, N. Rodríguez-Salas, J. Feliu, M. Rios, M. Mendiola
Journal: Annals of Oncology (2023)
SO-27 Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO
Authors: V. Conca, C. Antoniotti, F. Bergamo, F. Pietrantonio, D. Rossini, M. Scartozzi, E. Perissinotto, A. Leone, V. Pusceddu, B. Borelli, L. Cavanna, T. Latiano, D. Santini, G. Masi, L. Salvatore, G. Frassineti, F. Leone, S. Tamberi, L. Boni, C. Cremolini
Journal: Annals of Oncology (2023)
P-190 NALIRIFOX (iposomal irinotecan + 5-fluorouracil/feucovorin + oxaliplatin) versus FOLFOX [5-fluorouracil/leucovorin + oxaliplatin] as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall survival
Authors: E. O'Reilly, J. Li, M. DerSarkissian, R. Chang, M. Cheng, L. Yu, D. Rane, l. Zhang, Z. Xiao, F. Benzaghou, M. Duh, H. Chen
Journal: Annals of Oncology (2023)
O-10 Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) versus chemo (C)
Authors: M. Moehler, L. Wyrwicz, C. Chen, E. Davenport, J. Wang, R. Nathani, K. Kondo, E. Elimova
Journal: Annals of Oncology (2023)
P-96 Circulating tumor-derived DNA (ctDNA) clearance in patients with locally advanced rectal cancer treated with multimodal treatment
Authors: L. Gervaso, D. Ciardiello, L. Ascione, L. Boldrini, L. Guidi, C. Valenza, G. Gregato, L. Funicelli, L. Bottiglieri, G. De Roberto, W. Petz, S. Borin, U. Fumagalli Romario, M. Gerardi, F. Bertolini, G. Curigliano, N. Fazio, M. Zampino
Journal: Annals of Oncology (2023)
P-395 Induction chemotherapy followed by response evaluation and esophagectomy for advanced esophageal cancer
Authors: C. van der Zijden, P. van der Sluis, B. Mostert, J. Nuyttens, M. Spaander, E. Toxopeus, R. Valkema, S. Lagarde, B. Wijnhoven
Journal: Annals of Oncology (2023)
P-298 Adjuvant chemotherapy in resected lung-limited metastatic patients with colorectal cancer
Authors: P. Ziranu, P. Ferrari, F. Guerrera, P. Bertoglio, A. Tamburrini, P. Lyberis, A. Pretta, G. Grimaldi, E. Lai, M. Santoru, M. Dubois, A. Murenu, F. Bardanzellu, M. Puzzoni, F. Mathieu, A. Alzetani, L. Luzzi, P. Solli, P. Paladini, E. Ruffini, R. Cherchi, M. Scartozzi
Journal: Annals of Oncology (2023)
P-88 Epithelial-to-mesenchymal transition: An emerging prognostic tool in resectable pancreatic cancer, a retrospective study
Authors: A. Machmouchi, L. Zahreddine, J. Aoun, M. Charafeddine, L. Chehade, S. Temraz, A. Shamseddine
Journal: Annals of Oncology (2023)
P-158 The algorithm of esophagectomy technique selection in surgical treatment of squamous cell carcinoma and adenocarcinoma of esophagus
Authors: E. Levchenko, N. Khandogin, R. Yurin, N. Levchenko, O. Mamontov, S. Yergnyan, D. El-Kheiba
Journal: Annals of Oncology (2023)
P-81 Single-center real-world experience from 18 consecutive cases treated with durvalumab in combination with chemotherapy for advanced biliary tract cancer
Authors: D. Zhang, V. Heinemann, M. Haas, K. Heinrich, L. Weiss, M. Boukovala, V. Probst, R. Anna, G. Beyer, M. von Bergwelt-Baldion, B. Westphalen, S. Boeck, K. Dorman
Journal: Annals of Oncology (2023)
P-192 Real-world experience with trifluridine/tipiracil on metastatic colorectal cancer in a third level hospital
Authors: D. Rosero Rodríguez, P. Perez de Aguado, J. Chamorro Perez, V. Albarrán Fernandez, F. Longo, P. Reguera Puertas, M. Delfrade, R. Fuentes Mateos, C. Guillén-Ponce, V. López Gómez, M. Rodriguez Garrote, M. Vaz, M. Villamayor Delgado, J. Fernandez Fradejas, P. Garrido, M. Gil, J. Pozas, E. Gemeno López, P. Sotoca Rubio, V. Alía Navarro, A. Barrill Corpa, R. Ferreiro Monteagudo
Journal: Annals of Oncology (2023)
P-261 Oxaliplatine plus fluoropyrimidine versus fluoropyrimidine monotherapy as adjuvant treatment for stage III resected colorectal cancer (CRC) in older population, a single centre experience
Authors: I. Ruiz-Gutierrez, D. Jimenez-Bou, J. Peña, D. Martinez Perez, S. Martinez-Recio, D. Viñal, M. Alameda, G. Martin-Montalvo, A. Rueda-Lara, J. Garcia-Cuesta, J. Pedregosa Barbas, R. Marcano, A. Garcia-Leal, P. Zwisler Contreras, J. Perez-Wert, A. Custodio, I. Ghanem, N. Rodríguez-Salas, J. Feliu
Journal: Annals of Oncology (2023)
O-1 Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial
Authors: Z. Wainberg, D. Melisi, T. Macarulla, R. Pazo Cid, S. Chandana, C. de la Fouchardière, A. Dean, I. Kiss, W. Lee, T. Goetze, E. Van Cutsem, S. Paulson, T. Bekaii-Saab, S. Pant, R. Hubner, Z. Xiao, H. Chen, F. Benzaghou, E. O'Reilly
Journal: Annals of Oncology (2023)
P-269 Efficacy and safety of doublet adjuvant chemotherapy for elderly patients with stage III colorectal cancer
Authors: S. Silva, H. Guedes, E. Neto, A. Guedes, J. Cabral, B. Pereira, I. Leão, M. Castelo Branco, A. Monteiro, R. Basto, A. Capela, A. Moreira Pinto, S. Custódio, J. Marinho
Journal: Annals of Oncology (2023)
P-155 Surufatinib plus doublet (FOLFOX/FOLFIRI) or triplet (FOLFOXIRI) chemotherapy as second-line therapy in metastatic colorectal cancer (mCRC): First-stage results of a randomized, open-label phase II trial
Authors: R. Lin, H. Li, X. Chen, L. Zheng, Y. Hong, L. Su, C. Li, S. Zheng, L. Su
Journal: Annals of Oncology (2023)
P-199 Comparison of treatment outcomes of regorafenib for patients with metastatic colorectal cancer by era: A propensity-score matched analysis
Authors: T. Ogata, K. Harada, T. Kawakami, Q. Hu, S. Kadowaki, H. Taniguchi, K. Muro, T. Yamamura, Y. Kawamoto, Y. Komatsu, K. Fushiki, K. Oshima, R. Nakanishi, K. Ando, S. Nambara, T. Masuishi, K. Yamazaki, E. Oki, S. Yuki
Journal: Annals of Oncology (2023)
P-372 Inflammatory status as a predictor of resectability in borderline resectable pancreatic cancer
Authors: M. Goncalves, C. Teixeira, C. Almeida, M. Freitas, M. Couto, T. Lemos, I. Rego, A. Coelho, C. Sarmento, M. Barbosa, S. Meireles
Journal: Annals of Oncology (2023)
P-302 Survival impact of fluoropyrimidine dose adjustment in DPD deficient colorectal cancer patients: A single center experience
Authors: D. Martinez Perez, I. Ghanem, J. Peña, I. Ruiz-Gutierrez, D. Jimenez-Bou, D. Viñal, A. Custodio, J. Feliu, R. Rosas
Journal: Annals of Oncology (2023)
P-266 Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
Authors: D. Cowzer, M. Capanu, F. Keane, D. Khalil, J. Shia, R. Do, J. Chou, H. Walch, I. El Dika, A. Yaqubie, D. Solit, M. Berger, E. O'Reilly, J. Harding, G. Abou-Alfa
Journal: Annals of Oncology (2023)
SO-25 Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO
Authors: Y. Sunakawa, M. Shiozawa, T. Watanabe, H. Ota, H. Yasui, M. Kochi, D. Manaka, H. Ohori, T. Yamaguchi, T. Kyogoku, T. Sagawa, Y. Kubota, T. Masuishi, M. Kotaka, T. Sekikawa, K. Shimada, M. Nakamura, M. Takeuchi, W. Ichikawa, M. Fujii, A. Tsuji
Journal: Annals of Oncology (2023)
P-353 Outcomes of phosphorus-32 microparticle intratumoural implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinoma
Authors: A. Lim, N. Singhal, D. Bartholomeusz, J. Zobel, J. Naidu, W. Hsieh, B. Crouch, H. Wasan, D. Turner, N. Nguyen
Journal: Annals of Oncology (2023)
PD-22 RAS-mutations in population-based and real-life metastatic colorectal cancer cohorts
Authors: E. Osterlund, A. Ristimäki, S. Kytölä, E. Heervä, A. Uutela, T. Muhonen, P. Halonen, R. Kallio, L. Soveri, J. Sundström, A. Ålgars, R. Ristamäki, H. Sorbye, P. Pfeiffer, L. Nunes, T. Salminen, A. Lamminmäki, M. Mäkinen, T. Sjöblom, H. Isoniemi, B. Glimelius, P. Osterlund
Journal: Annals of Oncology (2023)
P-340 Bidirectional chemotherapy for patients with gastrointestinal peritoneal carcinomatosis
Authors: C. Smolenschi, A. Hollebecque, M. Valéry, A. Boileve, L. Antoun, A. Tarabay, T. Pudlarz, R. Eid, L. Benhaim, I. Sourrouille, M. Gelli, E. Fernandez de Sevilla, M. Ducreux, V. Boige
Journal: Annals of Oncology (2023)
PD-8 HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2+ advanced stomach cancer – correlation of the antibody responses and clinical outcome
Authors: J. Tobias, M. Kundi, E. Garner-Spitzer, C. Zielinski, M. Maglakelidze, Z. Andric, Z. Petrovic, R. Nagarkar, T. Chawla, L. Chong, B. Nixon, S. Yavrom, N. Ede, U. Wiedermann
Journal: Annals of Oncology (2023)
PD-16 Atezolizumab plus bevacizumab is associated with improved survival outcomes in HCC patients with Child-Pugh B dysfunction compared to best supportive therapy
Authors: C. Fulgenzi, A. D'Alessio, B. Scheiner, C. Ang, B. Wietharn, M. Pinter, N. Nishida, A. Parisi, Y. Huang, D. Bettinger, A. Vogel, M. Silletta, M. Schönlein, P. Galle, M. Kudo, A. Singal, A. Cortellini, H. Chon, B. Stefanini, E. Giannini, D. Pinato
Journal: Annals of Oncology (2023)
P-227 A phase II trial evaluating the Activity of caBozantinib in pre-treated pAtients with metastatic COlorectal cancer (mCRC): ABACO trial
Authors: G. Martini, T. Troiani, D. Ciardiello, S. Napolitano, V. Famiglietti, L. Esposito, G. Arrichiello, V. De Falco, C. Cardone, E. Maiello, T. Latiano, M. Di Bisceglie, E. Varriale, P. Vitiello, A. Bardelli, E. Mariella, A. Avallone, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2023)
P-54 Circulating immune cells as a tool to predict benefit from atezolizumab/bevacizumab in advanced hepatocellular carcinoma (aHCC)
Authors: F. Salani, V. Guerri, S. Cesario, P. Sammuri, V. Genovesi, F. Pratesi, V. Massa, S. Catanese, C. Vivaldi, L. Fornaro, F. Crea, P. Migliorini, S. Galimberti, G. Masi
Journal: Annals of Oncology (2023)
P-110 Epidemiological and clinicopathological features of early- (EOPC) and late-onset pancreatic cancer (LOPC) patients (pts): A mono-institutional retrospective analysis
Authors: M. Bensi, L. Salvatore, J. Lenkowicz, C. Bagalà, D. Barone, C. Iacomini, M. Chiaravalli, E. Gurreri, N. Di Giorgi, A. Spring, V. Beccia, A. Di Bello, G. Trovato, G. Quero, S. Alfieri, V. Valentini, G. Tortora
Journal: Annals of Oncology (2023)
P-107 Real-world screening and consensus based on practices and evidence (SCOPE) in gastrointestinal cancers: Practice patterns in metastatic pancreatic cancer
Authors: G. Prager, T. Fujii, D. Santini, D. Modest, F. Rivera, J. Phelip, M. Dioca, E. Smyth, A. Zaanan, H. Wasan, S. Boeck
Journal: Annals of Oncology (2023)
SO-24 Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase 2 VELO trial
Authors: D. Ciardiello, S. Napolitano, V. De Falco, G. Martini, E. Martinelli, C. Della Corte, L. Esposito, V. Famiglietti, A. Di Liello, A. Avallone, C. Cardone, A. De Stefano, V. Montesarchio, M. Zampino, N. Fazio, S. Del Tufo, M. Di Maio, F. De Vita, L. Altucci, F. Marrone, F. Ciardiello, T. Troiani
Journal: Annals of Oncology (2023)
SO-11 Bemarituzumab for treatment of previously untreated advanced and/or metastatic gastric and gastroesophageal cancer (GC): Final analysis of a randomized phase 2 trial (FIGHT)
Authors: Z. Wainberg, Y. Kang, K. Lee, S. Qin, K. Yamaguchi, I. Kim, A. Saeed, S. Oh, J. Li, H. Turk, A. Teixeira, E. Hitre, A. Udrea, G. Cardellino, R. Guardeño Sanchez, A. Zahlten-Kümeli, K. Taylor, P. Enzinger
Journal: Annals of Oncology (2023)
SO-4 Impact of molecular profiling on survival in patients with advanced biliary tract cancers
Authors: L. Antoun, I. Deneche, A. Boileve, A. Tarabay, E. Rouleau, E. El Rawadi, R. Eid, L. Lacroix, M. Valéry, V. Boige, P. Dartigues, M. Bani, C. Smolenschi, J. Scoazec, M. Ducreux, A. Hollebecque, D. Malka
Journal: Annals of Oncology (2023)
P-104 Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
Authors: C. Zhou, J. Zhang, J. Wu, J. Jiang, L. Zhu, J. Yan, C. Wang, Y. Mao, X. Tang, J. Chen, C. Wang, Z. Qin, Z. Han, X. Wei, C. Shangguan
Journal: Annals of Oncology (2023)
P-295 Retrospective cohort study of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer: A real-world data from 4 hospitals in Portugal
Authors: M. Menezes, J. Araújo, F. Fonseca, D. Neto da Silva, C. Trabulo, I. Dunoes, G. Baió, I. Bastos, A. Oliveira, M. Inácio, R. Dinis
Journal: Annals of Oncology (2023)